Now approved For dystrophic epidermolysis bullosa (DEB)
in patients aged 6 months or older1

VYJUVEK is the FIRST and ONLY treatment that addresses the genetic cause of DEB to provide powerful wound healing in a topical gel.1

Wound healing was evaluated in a clinical study comparing VYJUVEK with placebo. The main measure of the study was complete wound healing at 6 months. 65% of wounds treated with VYJUVEK healed completely at 6 months compared to 26% of wounds treated with placebo.1
VYJUVEK is supplied in a 5×109 PFU/mL single-use vial.
See the Press Release for more information.

Learn more about VYJUVEK

Download VYJUVEK Patient Brochure

Krystal Connect provides personalized support for people living with DEB

Krystal Connect™ logo

Krystal Connect is a patient support program designed to help people with DEB and their care partners throughout their unique DEB journey.

A dedicated team at Krystal Connect can provide ongoing assistance with:

  • Resources and education about DEB
  • Information about VYJUVEK
  • Financial assistance options for those eligible
  • Site of care logistics

The first step is having a healthcare professional complete this enrollment form.
This allows Krystal Connect to begin working with eligible patients.

Download Enrollment Form

To contact Krystal Connect or request more information:

INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

Reference: 1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.

IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE

VYJUVEK is a topical gel used to treat wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB).

IMPORTANT SAFETY INFORMATION

VYJUVEK gel must be applied by a healthcare provider.

After treatment, patients and caregivers should be careful not to touch treated wounds and dressings for 24 hours. If accidentally exposed to the VYJUVEK gel, clean the affected area.

Wash hands and wear protective gloves when changing wound dressings. Disinfect bandages from the first dressing change with a virucidal agent, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings in a sealed plastic bag in household waste.

Patients should avoid touching or scratching wound sites or wound dressings.

The most common adverse reactions (>5%) were itching, chills, redness, rash, cough, and runny nose. These are not all the possible side effects with VYJUVEK. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or to the Sponsor at 1-844-557-9782.

Reference: 1. VYJUVEK [prescribing information]. Krystal Biotech, Inc.; 2023.